Abstract Cyclin-dependent kinase (CDK) 4/6 inhibition in combination with endocrine
therapy is the standard-of-care treatment for patients with advanced-stage hormone receptor …

Endocrine therapy (ET) with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) is currently the
standard first-line treatment for most patients with hormone receptor (HR) positive, human …

Endocrine therapy is the main treatment for hormone receptor-positive (HR+) breast cancer.
However, advanced tumors develop resistance to endocrine therapy, rendering it ineffective …

Abstract Cyclin-Dependent Kinase 4/6 inhibitors (CDK4/6is) in combination with Endocrine
Therapy (ET) represent the standard frontline therapy for patients with Hormone Receptor …

Aurora kinases (AURKs) are a family of serine/threonine protein kinases that have a crucial
role in cell cycle process mainly in the event of chromosomal segregation, centrosome …

SMARCA4-deficient undifferentiated thoracic tumor is extremely invasive. This tumor with
poor prognosis is easily confused with SMARCA4-deficent non-small cell lung cancer or …

Breast cancer arises from a series of molecular alterations that disrupt cell cycle
checkpoints, leading to aberrant cell proliferation and genomic instability. Targeted …

Abstract A cyclin-dependent kinase 4/6 (CDK4/6) inhibitor combined with endocrine therapy
is the standard-of-care for patients with hormone receptor-positive/human epidermal growth …

The therapeutic landscape for hormone receptor-positive (HR+) breast carcinoma has
undergone a significant transformation with the advent of cyclin-dependent kinase (CDK) 4/6 …

Community cohesion plays a critical role in the determination of an individual's health in
social science. Intriguingly, a community structure of gene networks indicates that the …